Healthcare entity
All 1 tracked stories fall under one category: market-trends. Rezlidhia is most often covered alongside Caldolor, which appears in 1 of these 1 story. They are less corroborated than the beat average, carrying 2 original sources each against 2.8 for the same window.
Last mentioned: Mar 5, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: market-trends. Rezlidhia is most often covered alongside Caldolor, which appears in 1 of these 1 story. They are less corroborated than the beat average, carrying 2 original sources each against 2.8 for the same window. The 5 average consequence score is below the beat benchmark of 5.8 in the same window. We currently track 1 Healthcare story that mention Rezlidhia, all published on March 5, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 25 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Rezlidhia. Shared-story counts are live from our verified record — not editorial picks.
Rigel and Cumberland Pharmaceuticals reported Q4 results highlighting steady commercial growth in specialty oncology and hospital-based therapies. Both companies are prioritizing portfolio optimization and pipeline advancement to navigate a competitive biotech landscape.
Source: finance.yahoo.com · finance.yahoo.com
Rezlidhia is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
